Photo
Language
English
Title and Department
Professor of Medicine
Department of Medicine, Division of Nephrology and Hypertension
Professional bio
Julia (Breyer) Lewis, MD, is a Professor of Medicine in the Division of Nephrology and Hypertension within the Department of Medicine at Vanderbilt University Medical Center.
Dr. Julia Lewis’ area of research is the design and conduct of multi-center renal clinical trials where she has had leadership roles in numerous NIH-sponsored clinical trials including the MDRD, AASK, HEMO, pilot Diabetic Nephropathy Trial and the SPRINT Trial. In these trials, in addition to being the PI at the Vanderbilt high-enrolling and high-performing center, she has also had numerous leadership roles for the overall trial including serving on or leading the protocol design, form design, intervention, htn management, outcome classification and publication committees.
Dr. Lewis has played key roles in the Collaborative Study Group (CSG), an independent ARO, sitting on its executive committee for over 20 years in charge of protocol development. She has served as president of the CSG, and its coordinating center and all its central activities have transferred to Vanderbilt. The CSG has been responsible for key clinical trials in nephrology including ones leading to FDA approval of captopril and irbesartan for diabetic nephropathy and ferric citrate as a phosphate binder for dialysis patients. Currently, She serves as head of several NIH and industry sponsored oversight /advisory panels. She has completed a term as a member of the cardio-renal FDA Advisory Board as well as chair of the cardio-renal panel and currently has been asked to serve a second term as chair.
Julia Breyer Lewis, MD, has over 200 publications in peer-approved journals and has served as the nephrology fellowship director for over 25 years.
Dr. Julia Lewis’ area of research is the design and conduct of multi-center renal clinical trials where she has had leadership roles in numerous NIH-sponsored clinical trials including the MDRD, AASK, HEMO, pilot Diabetic Nephropathy Trial and the SPRINT Trial. In these trials, in addition to being the PI at the Vanderbilt high-enrolling and high-performing center, she has also had numerous leadership roles for the overall trial including serving on or leading the protocol design, form design, intervention, htn management, outcome classification and publication committees.
Dr. Lewis has played key roles in the Collaborative Study Group (CSG), an independent ARO, sitting on its executive committee for over 20 years in charge of protocol development. She has served as president of the CSG, and its coordinating center and all its central activities have transferred to Vanderbilt. The CSG has been responsible for key clinical trials in nephrology including ones leading to FDA approval of captopril and irbesartan for diabetic nephropathy and ferric citrate as a phosphate binder for dialysis patients. Currently, She serves as head of several NIH and industry sponsored oversight /advisory panels. She has completed a term as a member of the cardio-renal FDA Advisory Board as well as chair of the cardio-renal panel and currently has been asked to serve a second term as chair.
Julia Breyer Lewis, MD, has over 200 publications in peer-approved journals and has served as the nephrology fellowship director for over 25 years.